Last updated: November 6, 2026
Foradil Certihaler does not have a clear standalone commercial or regulatory record in the United States. Public FDA records identify Foradil as formoterol fumarate inhalation powder marketed through the Aerolizer device, not as a sustained U.S. product named Foradil Certihaler. The product’s commercial trajectory was therefore tied to the broader Foradil franchise: initial uptake in long-acting bronchodilation, erosion from competing inhaled therapies, generic formoterol entry, and eventual loss of branded economic value.
The principal business conclusion is that Foradil Certihaler had limited durable market value as a standalone asset. Its economics depended on formoterol, the delivery device, regulatory approvals, and physician familiarity. Once generic formoterol inhalation products entered the U.S. market, the remaining value shifted from the brand to manufacturing scale, device usability, distribution contracts, and combination-product portfolios.
What was Foradil Certihaler?
Foradil contained formoterol fumarate, a long-acting beta-2 adrenergic agonist used for maintenance treatment of bronchoconstriction in asthma and chronic obstructive pulmonary disease. The U.S. Foradil product was supplied as capsules containing inhalation powder used with the Aerolizer inhaler. The product was not an oral capsule and was not intended to be swallowed.
Certihaler was a multidose dry-powder inhaler platform associated with inhaled respiratory products. Public regulatory and commercial records do not establish Foradil Certihaler as a major U.S. marketed product with independently reported revenue. The commercially relevant U.S. product was Foradil Aerolizer.
| Product attribute |
Publicly established position |
| Active ingredient |
Formoterol fumarate |
| Therapeutic class |
Long-acting beta-2 agonist |
| Main indications |
Asthma maintenance and COPD maintenance |
| U.S. brand |
Foradil Aerolizer |
| Manufacturer associated with U.S. product |
Novartis Pharmaceuticals |
| Dosage form |
Inhalation powder capsule |
| U.S. regulatory pathway |
New Drug Application 020691 |
| Certihaler status |
No clearly documented standalone U.S. commercial franchise |
| Current branded value |
Low to negligible relative to combination inhalers and generics |
FDA labeling warned that long-acting beta-2 agonists should not be used as monotherapy for asthma. Foradil was used with an inhaled corticosteroid in asthma management, while COPD treatment could involve long-acting bronchodilator use under the approved labeling. [1]
When did Foradil lose exclusivity?
Foradil’s practical exclusivity eroded before and during the broader transition from single-agent bronchodilators to combination inhalers. The commercial decline resulted from three forces:
- Expiration or weakening of key composition, formulation, and device protection.
- Competition from other long-acting bronchodilators.
- Generic formoterol fumarate inhalation powder approvals.
The exact expiration of every patent associated with a named inhaler is difficult to reduce to one date because pharmaceutical exclusivity can include active-ingredient patents, formulation patents, device patents, manufacturing patents, and method-of-use patents. FDA’s Orange Book lists patents and regulatory exclusivity associated with approved products, but the Orange Book does not create a separate Foradil Certihaler estate where the product is not separately approved and listed.
Foradil exclusivity timeline
| Period |
Commercial and regulatory development |
| 1990s |
Foradil developed and introduced as a long-acting inhaled formoterol product |
| 1998 |
FDA approval of Foradil inhalation powder under NDA 020691 is reflected in FDA product records |
| 2000s |
Formoterol competes with salmeterol, inhaled corticosteroid combinations, and newer long-acting bronchodilators |
| 2010s |
Brand pricing pressure increases as respiratory prescribers move toward combination maintenance products |
| 2017 onward |
FDA records show generic formoterol fumarate inhalation powder approvals, increasing substitution risk |
| Late 2010s and after |
Foradil’s standalone branded commercial role declines materially |
The relevant economic date is not only the expiry of the earliest patent. Generic entry depends on whether an applicant can obtain approval, challenge listed patents, use a non-infringing device, or wait for the relevant patents and exclusivities to expire.
What patents protected Foradil and its inhaler?
The Foradil patent position likely involved multiple protection layers rather than one decisive patent. The relevant categories were:
Active-ingredient patents
Formoterol was discovered and developed before Foradil commercialization. Core compound protection would have provided the earliest and strongest exclusivity, but those rights were old by the time modern generic inhaler competition developed.
Formulation patents
Formoterol inhalation powder requires control of particle size, carrier particles, powder flow, dose uniformity, and emitted dose. Formulation claims can cover:
- Formoterol fumarate powder composition.
- Lactose or other carrier systems.
- Particle-size distribution.
- Stabilizers and excipients.
- Metered or capsule-based dose delivery.
- Manufacturing conditions that preserve inhalation performance.
Device patents
The Aerolizer and any Certihaler configuration could have generated separate device claims covering:
- Capsule piercing.
- Powder dispersion.
- Airflow paths.
- Dose counting.
- Multidose reservoirs.
- User actuation.
- Resistance and deaggregation characteristics.
A device patent does not necessarily block all generic formoterol products. A generic applicant can use a different inhaler architecture or certify that the relevant device claims are invalid or not infringed.
Method-of-use patents
Method-of-use claims could cover treatment of asthma, COPD, bronchospasm, or dosing schedules. Their commercial value was constrained by physician use, labeling, and the ability of generic applicants to omit patented indications through a section viii statement or use a narrower label.
What is the Orange Book status of Foradil?
The Orange Book is relevant to Foradil Aerolizer, not necessarily to a separately branded Foradil Certihaler. FDA’s Drugs@FDA and Orange Book systems should be read together because product names, NDA records, patent listings, and marketing-status entries can change over time. [2]
The commercially important regulatory points are:
- Foradil’s U.S. approval was associated with NDA 020691.
- The approved product was Foradil inhalation powder for oral inhalation.
- The delivery system was the Aerolizer inhaler.
- Orange Book protection would have been tied to the approved product and listed patents, not to every international device name.
- A foreign Certihaler product would not automatically create U.S. approval or U.S. Orange Book protection.
The U.S. status of Foradil should therefore not be described as an active, independently protected Certihaler franchise without a specific FDA approval record supporting that conclusion.
Which companies challenged Foradil patents?
Publicly visible generic activity centered on formoterol fumarate inhalation powder rather than a distinct Foradil Certihaler product. Generic applicants could pursue abbreviated new drug applications using one or more of the following strategies:
- Paragraph IV certification against listed patents.
- Paragraph III certification with a delayed approval date.
- Section viii carve-outs for method-of-use claims.
- Non-infringing inhaler designs.
- Alternative formulation and manufacturing processes.
The record does not establish a single, commercially dominant Paragraph IV litigation campaign specifically directed at a Foradil Certihaler product. Generic competition instead developed through the broader formoterol inhalation market.
What generic entry risks exist for Foradil?
Generic entry risk was high because the active ingredient was well established, clinical use was mature, and the product had an identifiable reference drug. The main technical obstacles were inhaler performance and bioequivalence, not discovery of new pharmacology.
Generic development barriers
A generic formoterol inhalation product must address:
- Delivered-dose uniformity.
- Fine-particle dose.
- Aerodynamic particle-size distribution.
- Device resistance.
- Patient inspiratory-flow requirements.
- Powder deaggregation.
- Capsule or reservoir reliability.
- Stability and moisture control.
- Dose-counter or actuation consistency.
These requirements can delay approval, but they do not provide the durable market protection associated with a novel active ingredient. Once one or more generic products demonstrate acceptable performance, price competition can develop rapidly.
How did Foradil compare with competing inhaled therapies?
Foradil competed in a market that moved toward combination therapy and differentiated devices.
| Product or class |
Strategic position versus Foradil |
| Foradil formoterol |
Standalone long-acting beta-2 agonist; mature product |
| Serevent salmeterol |
Competing long-acting beta-2 agonist |
| Symbicort budesonide/formoterol |
Combination inhaled corticosteroid and formoterol; stronger maintenance positioning |
| Advair fluticasone/salmeterol |
Large combination-inhaler franchise with extensive physician familiarity |
| Spiriva tiotropium |
Long-acting muscarinic antagonist for COPD |
| Anoro Ellipta and similar products |
Newer long-acting bronchodilator combinations |
| Generic formoterol |
Price-based substitute for standalone formoterol use |
Symbicort was especially important because it used the same bronchodilator molecule, formoterol, in a combination product with an inhaled corticosteroid. That combination generally had greater strategic value than standalone Foradil in asthma maintenance.
What was the financial trajectory of Foradil?
Novartis did not generally report Foradil Certihaler revenue as a separate public line item. Public annual reports typically grouped respiratory products within broader therapeutic or franchise categories. As a result, a defensible standalone revenue series for Foradil Certihaler is not available from company financial reporting.
The financial trajectory can still be characterized:
1. Launch and adoption phase
Foradil benefited from the clinical value of rapid-onset, long-acting bronchodilation. Revenue growth depended on prescription volume, reimbursement, physician adoption, and the ability to establish the inhaler as a maintenance product.
2. Mature branded phase
Revenue became more exposed to:
- Formoterol competition.
- Salmeterol competition.
- Inhaled corticosteroid combinations.
- Hospital and payer formulary controls.
- Device preferences.
- Generic substitution expectations.
3. Decline phase
The product’s commercial position weakened as combination inhalers gained share and the standalone molecule matured. A branded inhaler with a capsule-based device also faced commercial pressure from newer multidose and integrated inhaler systems.
4. Post-generic phase
After generic formoterol products entered the U.S. market, the likely revenue pattern was lower branded volume, reduced net price, and greater dependence on residual brand loyalty or supply arrangements. The value of the product shifted from patent exclusivity to manufacturing efficiency and distribution access.
No reliable public source supports a separate Foradil Certihaler revenue figure, cumulative sales figure, or current product-level valuation. Any precise number presented as Certihaler revenue would conflate different Foradil presentations, geographies, or the broader formoterol market.
Were there licensing deals involving Foradil Certihaler?
The public record supports Novartis ownership and commercialization of the U.S. Foradil franchise. It does not establish a major standalone licensing transaction whose economics can be attributed specifically to Foradil Certihaler.
Respiratory-device development can involve third-party engineering, manufacturing, or technology licenses. Those arrangements do not necessarily transfer product exclusivity or create a separately reportable asset. The absence of separately disclosed deal economics limits valuation of any Certihaler-specific licensing rights.
What litigation affected Foradil?
The principal legal risk was likely ordinary pharmaceutical patent and generic-entry risk rather than continuing litigation around a distinct Certihaler product. Relevant disputes could involve:
- Orange Book patent certifications.
- Inhalation formulation claims.
- Device infringement.
- Paragraph IV notices.
- Product-specific labeling.
- Manufacturing-process patents.
- Settlement agreements governing generic launch dates.
A settlement cannot be assumed without a publicly identified case, docket, or agreement. Public materials reviewed for the product do not establish a current, material Foradil Certihaler settlement that would preserve significant brand exclusivity.
How strong is the Foradil patent estate?
The patent estate was stronger during the protected launch period than after generic formoterol development matured. Its residual strength can be assessed as follows:
| Protection category |
Historical strength |
Current commercial effect |
| Formoterol compound |
High at launch |
Low after expiry |
| Inhalation formulation |
Moderate to high |
Limited by design-around options |
| Aerolizer device |
Moderate |
Can be avoided with alternative devices |
| Certihaler device |
Unclear for U.S. commercial use |
No established standalone value |
| Method of use |
Moderate |
Vulnerable to label carve-outs |
| Manufacturing process |
Moderate |
May affect cost, not necessarily market entry |
| Brand and physician familiarity |
Moderate historically |
Declines after generic entry |
The overall estate is best characterized as mature and commercially weakened, with any remaining value concentrated in technical know-how rather than broad exclusionary rights.
What is the outlook for generic launch and revenue recovery?
A generic launch would be expected to follow a standard sequence:
- FDA approval of an inhalation powder product.
- Pharmacy substitution where permitted.
- Payer preference for lower-cost products.
- Brand price reductions or contracting.
- Declining brand prescription volume.
- Possible market consolidation among generic suppliers.
Foradil would have limited ability to recover revenue through price increases after generic entry. Potential residual value could come from authorized generic supply, international markets, institutional contracts, or licensing of device and manufacturing technology. Those channels would not restore the product to its protected-brand economics.
Key Takeaways
- Foradil Certihaler does not have a clearly documented standalone U.S. commercial or Orange Book position.
- The relevant U.S. product was Foradil Aerolizer, a formoterol fumarate inhalation powder product associated with NDA 020691.
- The product’s commercial value declined as formoterol matured and combination inhalers gained market share.
- Generic formoterol inhalation products created substantial substitution and pricing risk.
- Formulation and device patents could delay or complicate entry but were more vulnerable than compound patents.
- Novartis did not publicly report standalone Foradil Certihaler revenue.
- No material Certihaler-specific licensing transaction or active settlement can be established from the public record.
- The remaining asset value is concentrated in manufacturing, device know-how, distribution, and residual brand recognition.
FAQs About Foradil Certihaler
Is Foradil Certihaler still marketed in the United States?
No standalone U.S. commercial franchise is clearly established under that name. The documented U.S. Foradil product was Foradil Aerolizer.
What drug replaced Foradil?
No single product replaced Foradil in every use. Symbicort, generic formoterol, other long-acting bronchodilators, and inhaled corticosteroid combinations absorbed different portions of its clinical and commercial demand.
Is Foradil the same as formoterol?
Foradil is a brand containing formoterol fumarate. Formoterol is the active bronchodilator molecule.
Did Foradil have biologic or biosimilar competition?
No. Foradil is a small-molecule inhalation product. Its competitors are generic inhalation products and branded respiratory medicines, not biosimilars.
Can a generic formoterol inhaler use the Aerolizer device?
A generic applicant does not necessarily need to use the same device. It may use a different inhaler if it satisfies FDA requirements and does not infringe enforceable device claims.
References
-
U.S. Food and Drug Administration. (1998). Foradil Aerolizer prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Foradil and NDA 020691. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
-
Novartis AG. (Various years). Annual report. Novartis.
-
U.S. Food and Drug Administration. (Various years). Approved drug products and abbreviated new drug application records for formoterol fumarate inhalation powder. FDA.
